Kestra Medical (NASDAQ: KMTS) holder plans new sale after $1.27M August trade

Rhea-AI Filing Summary

Brian Webster filed a notice to sell 15,000 shares of Kestra Medical Technologies, Ltd. (KMTS) common stock through Merrill Lynch on 08/17/2026, with a proposed aggregate value of $412,180.90. These shares were granted on 07/14/2026 as a Performance Stock Issuance under the issuer’s equity compensation plan. The notice also lists several prior sales between April 15 and August 4, 2026, with individual transactions ranging from 7,857–51,900 shares and $178,531.04–$1,272,585.45 in proceeds.

Key Figures

Shares proposed to be sold: 15,000 shares Proposed aggregate sale value: $412,180.90 Proposed sale date: 08/17/2026 +5 more

8 metrics

Shares proposed to be sold 15,000 shares Common stock to be sold through Merrill Lynch

Proposed aggregate sale value $412,180.90 Estimated value of 15,000 shares to be sold on 08/17/2026

Proposed sale date 08/17/2026 Planned date for Form 144 sale of 15,000 shares

Grant date of shares 07/14/2026 Performance Stock Issuance under equity compensation plan

Largest recent single sale (shares) 51,900 shares KMTS common shares sold on 08/04/2026

Largest recent single sale (value) $1,272,585.45 Proceeds from 51,900-share sale on 08/04/2026

Smallest recent single sale (shares) 7,857 shares KMTS common shares sold on 07/30/2026

Value of smallest recent sale $178,531.04 Proceeds from 7,857-share sale on 07/30/2026

Key Terms

Form 144, Performance Stock Issuance, equity compensation plan

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Performance Stock Issuance financial

"Common Stock | 07/14/2026 | Performance Stock Issuance |"

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

FAQ

What does the KMTS Form 144 filed by Brian Webster disclose?

The Form 144 for KMTS discloses Brian Webster’s intent to sell 15,000 common shares on 08/17/2026. It also lists multiple prior sales of KMTS shares between April 15 and August 4, 2026, including one sale of 51,900 shares for $1,272,585.45.

How many KMTS shares does Brian Webster plan to sell under this Form 144?

Brian Webster plans to sell 15,000 shares of KMTS common stock in this Form 144 filing. The proposed transaction, routed through Merrill Lynch, carries an indicated aggregate value of $412,180.90, with the planned sale date shown as 08/17/2026 on NASDAQ.

What is the proposed dollar value of Brian Webster’s planned KMTS share sale?

The proposed sale of 15,000 KMTS shares has an aggregate indicated value of $412,180.90. This amount reflects the estimated market value for the planned sale through Merrill Lynch on 08/17/2026, as disclosed in the Form 144 securities information section.

How were the KMTS shares that Brian Webster plans to sell originally acquired?

The 15,000 KMTS shares covered by the Form 144 were acquired via a Performance Stock Issuance on 07/14/2026. The shares were granted as part of the issuer’s equity compensation plan, indicating they arose from compensation rather than an open-market purchase.

What recent KMTS share sales by Brian Webster are listed in the Form 144?

The filing lists several KMTS share sales from 04/15/2026 to 08/04/2026, with blocks of 15,000 shares sold on multiple monthly dates. Additional transactions include 7,857 shares for $178,531.04 and 51,900 shares for $1,272,585.45.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 04:52 PM Accepted by SEC EDGAR 08/17/2026 - 04:51 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St New York NY 10281	15000	412180.90	58602497	08/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/14/2026	Performance Stock Issuance	KESTRA MEDICAL TECHNOLOGIES, LTD.			15000	07/14/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	04/15/2026	15000	300671.04
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	05/15/2026	15000	314329.85
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 Common Shares WA 98033	Common Shares	06/15/2026	15000	312142.94
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	07/15/2026	15000	336609.41
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	07/30/2026	7857	178531.04
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	07/31/2026	8948	202259.77
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	08/03/2026	13017	311424.12
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	08/04/2026	51900	1272585.45

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)